"Brand_name","Drug_name_original","Drug_name","Sponsor","DrugId","Properties","Indication","Indication_EFO","DiseaseId","TA","Review_type","Year.x","targetIds","Year.y","has_GE"
"Lutathera","Lutetium Lu 177 dotatate","LUTETIUM LU 177 DOTATATE","Advanced Accelerator Applications/Novartis","CHEMBL3989924","Somatostatin receptor-targeted radiopharmaceutical","GEP-NETs","digestive system neuroendocrine neoplasm","MONDO_0024503","Oncology","P, O",2018,"ENSG00000139874; ENSG00000162009; ENSG00000278195; ENSG00000132671; ENSG00000180616",2018,TRUE
"Biktarvy","Bictegravir; emtricitabine; tenofovir alafenamide","BICTEGRAVIR","Gilead Sciences","CHEMBL3989866","HIV-1 integrase inhibitor and HIV-1 nucleoside/nucleotide reverse transcriptase inhibitors","HIV","hiv infection","EFO_0000764","Infectious","P",2018,"",NA,NA
"Biktarvy","Bictegravir; emtricitabine; tenofovir alafenamide","EMTRICITABINE","Gilead Sciences","CHEMBL885","HIV-1 integrase inhibitor and HIV-1 nucleoside/nucleotide reverse transcriptase inhibitors","HIV","hiv infection","EFO_0000764","Infectious","P",2018,"",NA,NA
"Biktarvy","Bictegravir; emtricitabine; tenofovir alafenamide","TENOFOVIR ALAFENAMIDE","Gilead Sciences","CHEMBL2107825","HIV-1 integrase inhibitor and HIV-1 nucleoside/nucleotide reverse transcriptase inhibitors","HIV","hiv infection","EFO_0000764","Infectious","P",2018,"",NA,NA
"Symdeko","Tezacaftor; ivacaftor","TEZACAFTOR","Vertex Pharmaceuticals","CHEMBL3544914","CFTR corrector and CFTR potentiator","Cystic fibrosis","cystic fibrosis","MONDO_0009061","Metabolic","P, O, B",2018,"ENSG00000001626; ENSG00000001626",2018,TRUE
"Symdeko","Tezacaftor; ivacaftor","IVACAFTOR","Vertex Pharmaceuticals","CHEMBL2010601","CFTR corrector and CFTR potentiator","Cystic fibrosis","cystic fibrosis","MONDO_0009061","Metabolic","P, O, B",2018,"ENSG00000001626; ENSG00000001626",2018,TRUE
"Erleada","Apalutamide","APALUTAMIDE","Johnson & Johnson","CHEMBL3183409","Androgen receptor inhibitor","Prostate cancer","prostate cancer","MONDO_0008315","Oncology","P",2018,"ENSG00000169083",2018,TRUE
"Trogarzo","Ibalizumab","IBALIZUMAB","TaiMed Biologics/Theratechnologies","CHEMBL1743029","CD4 antibody","HIV","hiv infection","EFO_0000764","Infectious","P, O, B",2018,"ENSG00000010610",2018,TRUE
"Ilumya","Tildrakizumab","TILDRAKIZUMAB","Sun Pharma","CHEMBL2108681","IL-23 antibody","Plaque psoriasis","psoriasis vulgaris","EFO_1001494","Dermatology","S",2018,"ENSG00000110944; ENSG00000113302",2018,TRUE
"Tavalisse","Fostamatinib","FOSTAMATINIB","Rigel Pharmaceuticals","CHEMBL2103830","SYK inhibitor","Immune thrombocytopenic purpura","autoimmune thrombocytopenic purpura","EFO_0007160","Hematology","S, O",2018,"ENSG00000165025",2018,TRUE
"Crysvita","Burosumab","BUROSUMAB","Ultragenyx Pharmaceutical/Kyowa Hakko Kirin","CHEMBL3707326","FGF23 antibody","X-linked hypophosphataemia","Hypophosphatemia","HP_0002148","Endocrine","P, O, B",2018,"ENSG00000118972",2018,TRUE
"Akynzeo IV","Palonosetron; fosnetupitant","PALONOSETRON","Helsinn Group","CHEMBL1189679","5-HT3-receptor antagonist and NK1-receptor antagonist","Chemotherapy-induced emesis","Chemotherapy-induced nausea and vomiting","EFO_0006911","Other","S",2018,"ENSG00000166736",2018,FALSE
"Akynzeo IV","Palonosetron; fosnetupitant","FOSNETUPITANT","Helsinn Group","CHEMBL3989917","5-HT3-receptor antagonist and NK1-receptor antagonist","Chemotherapy-induced emesis","Chemotherapy-induced nausea and vomiting","EFO_0006911","Other","S",2018,"ENSG00000115353",2018,FALSE
"Lucemyra","Lofexidine","LOFEXIDINE","US WorldMeds","CHEMBL17860","beta2-adrenoceptor agonist","Opioid withdrawal","opioid dependence","EFO_0005611","Other","P",2018,"ENSG00000150594; ENSG00000274286; ENSG00000184160",2018,FALSE
"Aimovig","Erenumab","ERENUMAB","Amgen/Novartis","CHEMBL3833329","CGRP receptor antibody","Migraine","migraine disorder","MONDO_0005277","Neurological","S",2018,"ENSG00000064989",2018,TRUE
"Lokelma","Sodium zirconium cyclosilicate","SODIUM ZIRCONIUM CYCLOSILICATE","AstraZeneca","CHEMBL3301592","Potassium binder","Hyperkalaemia","hyperkalemia","HP_0002153","Nephrology","S",2018,"",NA,NA
"Doptelet","Avatrombopag","AVATROMBOPAG","Dova Pharmaceuticals","CHEMBL2103883","Thrombopoietin receptor agonist","Thrombocytopenia","thrombocytopenia","HP_0001873","Hematology","P",2018,"ENSG00000117400",2018,TRUE
"Palynziq","Pegvaliase","PEGVALIASE","BioMarin Pharmaceutical","CHEMBL4297802","PAL replacement therapy","Phenylketonuria","phenylketonuria","MONDO_0009861","Metabolic","P, O",2018,"",NA,NA
"Olumiant","Baricitinib","BARICITINIB","Incyte/Eli Lilly","CHEMBL2105759","JAK inhibitor","Rheumatoid arthritis","rheumatoid arthritis","EFO_0000685","Immunology","S",2018,"ENSG00000096968; ENSG00000162434",2018,TRUE
"Moxidectin","Moxidectin","MOXIDECTIN","Medicines Development for Global Health","CHEMBL2104415","Antihelmintic GABA receptor and glutamate channel modulator","River blindness","ocular onchocerciasis","EFO_0007398","Other","P, O",2018,"",NA,NA
"Epidiolex","Cannabidiol","CANNABIDIOL","GW Pharmaceuticals","CHEMBL190461","Cannabinoid","Dravet syndrome and Lennox-Gastaut syndrome","Dravet syndrome; Lennox-Gastaut syndrome","Orphanet_33069; MONDO_0016532","Neurological","P, O",2018,"ENSG00000118432",2018,FALSE
"Zemdri","Plazomicin","PLAZOMICIN","Achaogen","CHEMBL1650559","Aminoglycoside antibacterial","Urinary tract infections","urinary tract infection","EFO_0003103","Infectious","P",2018,"",NA,NA
"Mektovi","Binimetinib","BINIMETINIB","Array BioPharma","CHEMBL3187723","MEK inhibitor","BRAF-mutated melanoma","melanoma","EFO_0000756","Oncology","S, O",2018,"ENSG00000126934; ENSG00000169032",2018,TRUE
"Braftovi","Encorafenib","ENCORAFENIB","Array BioPharma","CHEMBL3301612","BRAF inhibitor","BRAF-mutated melanoma","melanoma","EFO_0000756","Oncology","S, O",2018,"ENSG00000157764",2018,TRUE
"TPOXX","Tecovirimat","TECOVIRIMAT","SIGA Technologies","CHEMBL1257073","Viral p37 protein inhibitor","Smallpox","smallpox","MONDO_0004651","Infectious","P, O",2018,"",NA,NA
"Tibsovo","Ivosidenib","IVOSIDENIB","Agios Pharmaceuticals","CHEMBL3989958","IDH1 inhibitor","IDH1-mutated AML, Locally Advanced or Metastatic Cholangiocarcinoma (*)","acute myeloid leukemia; cholangiocarcinoma","EFO_0000222; EFO_0005221","Oncology","P, O",2018,"ENSG00000138413",2018,TRUE
"Krintafel","Tafenoquine","TAFENOQUINE","Medicines for Malaria Venture/GlaxoSmithKline","CHEMBL298470","8-Aminoquinoline antimalarial","Plasmodium vivax malaria","Plasmodium vivax malaria","EFO_0007445","Infectious","P, O, B",2018,"",NA,NA
"Orilissa","Elagolix sodium","ELAGOLIX SODIUM","AbbVie","CHEMBL502182","GnRH receptor antagonist","Pain associated with endometriosis","adenomyosis; pain","MONDO_0010888; EFO_0003843","Other","P",2018,"ENSG00000109163",2018,TRUE
"Omegaven","Fish oil triglycerides","FISH OIL TRIGLYCERIDES","Fresenius","CHEMBL4297535","Mixture of fatty acids","Parenteral nutrition-associated cholestasis","cholestasis","MONDO_0001751","Other","P, O",2018,"ENSG00000151067",2018,TRUE
"Mulpleta","Lusutrombopag","LUSUTROMBOPAG","Shionogi","CHEMBL2107831","Thrombopoietin receptor agonist","Thrombocytopenia","thrombocytopenia","HP_0001873","Hematology","P",2018,"ENSG00000117400",2018,TRUE
"Poteligeo","Mogamulizumab","MOGAMULIZUMAB","Kyowa Hakko Kirin","CHEMBL1743041","CCR4 antibody","mycosis fungoides or Sezary syndrome","mycosis fungoides","EFO_1001051","Oncology","P, O, B",2018,"ENSG00000183813",2018,TRUE
"Onpattro","Patisiran","PATISIRAN","Alnylam Pharmaceuticals","CHEMBL3989987","TTR-directed small interfering RNA","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Metabolic","P, O, B",2018,"ENSG00000118271",2018,TRUE
"Annovera","Segesterone acetate; ethinyl estradiol","SEGESTERONE ACETATE","TherapeuticsMD","CHEMBL3707377","Progestin and estrogen combined hormonal contraceptive","Female contraception","contraception","EFO_0009520","Other","S",2018,"ENSG00000082175",2018,TRUE
"Annovera","Segesterone acetate; ethinyl estradiol","ETHINYL ESTRADIOL","TherapeuticsMD","CHEMBL691","Progestin and estrogen combined hormonal contraceptive","Female contraception","contraception","EFO_0009520","Other","S",2018,"ENSG00000091831",2018,TRUE
"Galafold","Migalastat","MIGALASTAT","Amicus Therapeutics","CHEMBL110458","beta-galactosidase regulator","Fabry disease","fabry disease","MONDO_0010526","Metabolic","P, O, A",2018,"ENSG00000102393",2018,TRUE
"Diacomit","Stiripentol","STIRIPENTOL","Biocodex","CHEMBL1983350","GABA reuptake inhibitor","Dravet syndrome","dravet syndrome","Orphanet_33069","Neurological","P, O",2018,"ENSG00000022355",2018,TRUE
"Oxervate","Cenegermin","CENEGERMIN","Domp√©","CHEMBL4297852","Recombinant NGF","Neurotrophic keratitis","keratitis","EFO_0009449","Ophthalmology","P, O, B",2018,"ENSG00000140538; ENSG00000148053; ENSG00000198400",2018,TRUE
"Takhzyro","Lanadelumab","LANADELUMAB","Dyax/Shire","CHEMBL3545189","Kallikrein antibody","Hereditary angioedema","hereditary angioedema","MONDO_0019623","Immunology","P, O, B",2018,"ENSG00000164344",2018,FALSE
"Xerava","Eravacycline","ERAVACYCLINE","Tetraphase Pharmaceuticals","CHEMBL1951095","Tetracycline antibiotic","Complicated intra-abdominal infections","infectious disease","EFO_0005741","Infectious","P",2018,"",NA,NA
"Pifeltro","Doravirine","DORAVIRINE","Merck & Co.","CHEMBL2364608","NNRTI","HIV","hiv infection","EFO_0000764","Infectious","S",2018,"",NA,NA
"Lumoxiti","Moxetumomab pasudotox","MOXETUMOMAB PASUDOTOX","AstraZeneca","CHEMBL1743043","CD22-directed antibody‚Äìdrug conjugate","Hairy cell leukaemia","hairy cell leukemia","EFO_1000956","Oncology","P, O",2018,"ENSG00000167658; ENSG00000012124",2018,TRUE
"Ajovy","Fremanezumab","FREMANEZUMAB","Teva","CHEMBL4297756","CGRP antibody","Migraine","migraine disorder","MONDO_0005277","Neurological","P",2018,"ENSG00000110680; ENSG00000175868",2018,TRUE
"Copiktra","Duvelisib","DUVELISIB","Verastem","CHEMBL3039502","PI3K inhibitor","CLL, FL and SLL","chronic lymphocytic leukemia; follicular lymphoma","EFO_0000095; MONDO_0018906","Oncology","P, O, A",2018,"ENSG00000171608; ENSG00000105851",2018,TRUE
"Emgality","Galcanezumab","GALCANEZUMAB","Eli Lilly","CHEMBL3707328","CGRP antibody","Migraine","migraine disorder","MONDO_0005277","Neurological","S",2018,"ENSG00000175868; ENSG00000110680",2018,TRUE
"Vizimpro","Dacomitinib","DACOMITINIB","Pfizer","CHEMBL2105719","EGFR inhibitor","EGFR-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Oncology","P, O",2018,"ENSG00000178568; ENSG00000146648; ENSG00000141736",2018,TRUE
"Libtayo","Cemiplimab","CEMIPLIMAB","Regeneron/Sanofi","CHEMBL4297723","PD1 antibody","CSCC, BCC(*), NSCLC(*)","cutaneous squamous cell carcinoma; basal cell carcinoma; non-small cell lung carcinoma","EFO_1001927; EFO_0004193; EFO_0003060","Oncology","P, B",2018,"ENSG00000188389",2018,TRUE
"Seysara","Sarecycline","SARECYCLINE","Allergan","CHEMBL2364632","Tetracycline antibiotic","Severe acne vulgaris","acne","EFO_0003894","Dermatology","S",2018,"",NA,NA
"Nuzyra","Omadacycline","OMADACYCLINE","Paratek Pharmaceuticals","CHEMBL1689772","Tetracycline antibiotic","CABP and ABSSSI","bacterial pneumonia; skin disease caused by bacterial infection","EFO_1001272; MONDO_0024295","Other","P",2018,"",NA,NA
"Revcovi","Elapegademase","ELAPEGADEMASE","Leadiant Biosciences","CHEMBL3990026","Recombinant adenosine deaminase","ADA-SCID","severe combined immunodeficiency, autosomal recessive, t cell-negative, b cell-negative, nk cell-negative, due to adenosine deaminase deficiency","MONDO_0007064","Immunology","P, O",2018,"ENSG00000196839",2018,TRUE
"Tegsedi","Inotersen","INOTERSEN","Ionis Pharmaceuticals","CHEMBL4297770","TTR-directed antisense oligonucleotide","Hereditary TTR-mediated amyloidosis","hereditary ATTR amyloidosis","MONDO_0017132","Metabolic","P, O",2018,"ENSG00000118271",2018,TRUE
"Talzenna","Talazoparib","TALAZOPARIB","Pfizer","CHEMBL3137320","PARP inhibitor","BRCA-mutated HER2-negative breast cancer","HER2 negative breast carcinoma","EFO_0009780","Oncology","P",2018,"ENSG00000129484; ENSG00000143799",2018,TRUE
"Xofluza","Baloxavir marboxil","BALOXAVIR MARBOXIL","Shionogi/Roche","CHEMBL4297503","Polymerase acidic endonuclease inhibitor","Acute uncomplicated influenza","influenza","EFO_0007328","Infectious","P",2018,"",NA,NA
"Lorbrena","Lorlatinib","LORLATINIB","Pfizer","CHEMBL3286830","ALK and ROS1 inhibitor","ALK-positive NSCLC","non-small cell lung carcinoma","EFO_0003060","Oncology","P, O, B, A",2018,"ENSG00000143924; ENSG00000171094",2018,TRUE
"Yupelri","Revefenacin","REVEFENACIN","Theravance Biopharma/Mylan","CHEMBL3833319","Long-acting muscarinic receptor antagonist","COPD","chronic obstructive pulmonary disease","EFO_0000341","Respiratory","S",2018,"ENSG00000133019",2018,TRUE
"Aemcolo","Rifamycin","RIFAMYCIN","Cosmo Technologies","CHEMBL437765","Ansamycin antibacterial","Travellers diarrhoea","Diarrhea","HP_0002014","Other","P",2018,"",NA,NA
"Gamifant","Emapalumab","EMAPALUMAB","Novimmune","CHEMBL3989977","Interferon-Œ≥-blocking antibody","Primary haemophagocytic lymphohistiocytosis","genetic hemophagocytic lymphohistiocytosis","MONDO_0015541","Hematology","P, O, B",2018,"ENSG00000111537",2018,TRUE
"Daurismo","Glasdegib","GLASDEGIB","Pfizer","CHEMBL2043437","Hedgehog pathway inhibitor","AML",NA,"EFO_0000222","Oncology","P, O",2018,"ENSG00000128602",2018,TRUE
"Vitrakvi","Larotrectinib","LAROTRECTINIB","Loxo Oncology/Bayer","CHEMBL3889654","TRKA, TRKB and TRKC inhibitor","NTRK-positive solid cancers","salivary gland cancer; soft tissue sarcoma; thyroid cancer","MONDO_0004669; EFO_1001968; MONDO_0002108","Oncology","P, O, B, A",2018,"ENSG00000148053; ENSG00000198400; ENSG00000140538",2018,TRUE
"Xospata","Gilteritinib","GILTERITINIB","Astellas","CHEMBL3301622","FLT3 inhibitor","FLT3-positive AML","acute myeloid leukemia","EFO_0000222","Oncology","P, O, B",2018,"ENSG00000122025; ENSG00000167601",2018,TRUE
"Firdapse","Amifampridine","AMIFAMPRIDINE","Catalyst Pharmaceuticals","CHEMBL354077","Potassium channel blocker","Lambert-Eaton myasthenic syndrome","Lambert-Eaton myasthenic syndrome","Orphanet_43393","Neurological","P, O",2018,"ENSG00000130037; ENSG00000182255; ENSG00000173826; ENSG00000111262; ENSG00000178342; ENSG00000131398; ENSG00000140015; ENSG00000055118; ENSG00000168418; ENSG00000143473; ENSG00000183960; ENSG00000151079; ENSG00000184408; ENSG00000116396; ENSG00000171126; ENSG00000168263; ENSG00000026559; ENSG00000170745; ENSG00000185760; ENSG00000135519; ENSG00000184156; ENSG00000075043; ENSG00000117013; ENSG00000158445; ENSG00000166006; ENSG00000129159; ENSG00000124134; ENSG00000156486; ENSG00000143105; ENSG00000182674; ENSG00000053918; ENSG00000089558; ENSG00000177301; ENSG00000162975; ENSG00000102057; ENSG00000184611; ENSG00000171385; ENSG00000177272; ENSG00000104848; ENSG00000164794",2018,FALSE
"Motegrity","Prucalopride","PRUCALOPRIDE","Shire/Takeda","CHEMBL117287","5-HT4-receptor agonist","Chronic idiopathic constipation","constipation disorder","MONDO_0002203","Gastrointestinal","S",2018,"ENSG00000164270",2018,FALSE
"Asparlas","Calaspargase pegol","CALASPARGASE PEGOL","Servier","CHEMBL2108728","Asparagine specific enzyme","ALL","acute lymphoblastic leukemia","EFO_0000220","Oncology","S, O",2018,"ENSG00000166183",2018,FALSE
"Ultomiris","Ravulizumab","RAVULIZUMAB","Alexion","CHEMBL3989986","Complement inhibitor","Paroxysmal nocturnal haemoglobinuria, atypical hemolytic uremic syndrome (*), generalized myasthenia gravis AChR+ (*)","paroxysmal nocturnal hemoglobinuria, atypical hemolytic-uremic syndrome, Myasthenia gravis","MONDO_0100244; MONDO_0016244; EFO_0004991","Hematology","S, O",2018,"ENSG00000106804",2018,TRUE
"Elzonris","Tagraxofusp","TAGRAXOFUSP","Stemline Therapeutics","CHEMBL4297573","IL-3 and diphtheria toxin fusion protein","Blastic plasmacytoid dendritic cell neoplasm","blastic plasmacytoid dendritic cell neoplasm","EFO_0010580","Oncology","P, O, B",2018,"ENSG00000167658; ENSG00000185291",2018,FALSE
"Jeuveau","Prabotulinumtoxin A","PRABOTULINUMTOXIN A","Evolus","CHEMBL4297229","Acetylcholine release inhibitor and a neuromuscular blocking agent","Glabellar lines associated with corrugator and/or procerus muscle activity","Facial wrinkling","HP_0009762","Other","S",2019,"ENSG00000132639",2019,FALSE
"Cablivi","Caplacizumab","CAPLACIZUMAB","Sanofi/Ablynx","CHEMBL2109624","vWF-directed nanobody","ATTP","thrombotic thrombocytopenic purpura","MONDO_0018896","Hematology","P, O",2019,"ENSG00000110799",2019,TRUE
"Egaten","Triclabendazole","TRICLABENDAZOLE","Novartis","CHEMBL1086440","Anthelmintic","Fascioliasis","fascioliasis","EFO_1001324","Infectious","P, O",2019,"",NA,NA
"Zulresso","Brexanolone","BREXANOLONE","Sage Therapeutics","CHEMBL207538","GABAA-receptor-positive modulator","Postpartum depression","postpartum depression","EFO_0007453","Mental health","P, B",2019,"ENSG00000094755; ENSG00000109158; ENSG00000186297; ENSG00000022355; ENSG00000145864; ENSG00000166206; ENSG00000182256; ENSG00000011677; ENSG00000268089; ENSG00000102287; ENSG00000113327; ENSG00000163285; ENSG00000151834; ENSG00000145863; ENSG00000163288; ENSG00000187730",2019,TRUE
"Sunosi","Solriamfetol","SOLRIAMFETOL","Jazz","CHEMBL4297620","Dopamine and noradrenaline reuptake inhibitor","Excessive sleepiness due to narcolepsy or obstructive sleep apnoea","hypersomnia; narcolepsy; obstructive sleep apnea","EFO_0005246; MONDO_0021107; EFO_0003918","Other","S, O",2019,"ENSG00000142319; ENSG00000103546",2019,TRUE
"Mayzent","Siponimod","SIPONIMOD","Novartis","CHEMBL2336071","S1P receptor modulator","Relapsing forms of multiple sclerosis","relapsing-remitting multiple sclerosis","EFO_0003929","Neurological","S",2019,"ENSG00000170989; ENSG00000168610",2019,TRUE
"Evenity","Romosozumab","ROMOSOZUMAB","Amgen","CHEMBL2107874","Sclerostin inhibitor","Osteoporosis","osteoporosis","EFO_0003882","Endocrine","S",2019,"ENSG00000167941",2019,TRUE
"Balversa","Erdafitinib","ERDAFITINIB","Janssen /J&J","CHEMBL3545376","FGFR inhibitor","Bladder cancer","urinary bladder carcinoma","MONDO_0004986","Oncology","P, B, A",2019,"ENSG00000077782; ENSG00000066468; ENSG00000160867; ENSG00000068078",2019,TRUE
"Skyrizi","Risankizumab","RISANKIZUMAB","AbbVie","CHEMBL3990029","IL-23 antagonist","Plaque psoriasis","psoriasis vulgaris","EFO_1001494","Dermatology","S",2019,"ENSG00000110944; ENSG00000113302",2019,TRUE
"Vyndaqel","Tafamidis","TAFAMIDIS","Pfizer/Foldrx","CHEMBL2103837","Transthyretin stabilizer","Heart disease caused by ATTR-CM","cardiomyopathy","EFO_0000318","Cardiovascular","P, O, B",2019,"ENSG00000118271",2019,TRUE
"Piqray","Alpelisib","ALPELISIB","Novartis","CHEMBL2396661","PI3K inhibitor","Breast cancer","breast cancer","MONDO_0007254","Oncology","P",2019,"ENSG00000121879",2019,TRUE
"Polivy","Polatuzumab vedotin","POLATUZUMAB VEDOTIN","Roche","CHEMBL3301582","CD79b-directed ADC","Diffuse large B-cell lymphoma","diffuse large b-cell lymphoma","EFO_0000403","Oncology","P, O, B, A",2019,"ENSG00000198033; ENSG00000167552; ENSG00000261456; ENSG00000176014; ENSG00000258947; ENSG00000123416; ENSG00000101162; ENSG00000188229; ENSG00000152086; ENSG00000007312; ENSG00000137285; ENSG00000167553; ENSG00000196230; ENSG00000137267; ENSG00000127824; ENSG00000104833",2019,TRUE
"Vyleesi","Bremelanotide","BREMELANOTIDE","Amag","CHEMBL2070241","Melanocortin receptor agonist","Hypoactive sexual desire disorder","sexual dysfunction","EFO_0004714","Other","S",2019,"ENSG00000166603",2019,FALSE
"Xpovio","Selinexor","SELINEXOR","Karyopharm Therapeutics","CHEMBL3545185","XPO1 inhibitor","Multiple myeloma","multiple myeloma","EFO_0001378","Oncology","P, O, A",2019,"ENSG00000082898",2019,TRUE
"Recarbrio","Cilastatin; imipenem; relebactam","CILASTATIN","Merck & Co.","CHEMBL766","A renal dehydropeptidase inhibitor, a penem antibacterial and a beta-lactamase inhibitor","Complicated urinary tract and complicated intra-abdominal infections","urinary tract infection","EFO_0003103","Infectious","P",2019,"ENSG00000015413",2019,FALSE
"Recarbrio","Cilastatin; imipenem; relebactam","IMIPENEM","Merck & Co.","CHEMBL148","A renal dehydropeptidase inhibitor, a penem antibacterial and a beta-lactamase inhibitor","Complicated urinary tract and complicated intra-abdominal infections","urinary tract infection","EFO_0003103","Infectious","P",2019,"",2019,FALSE
"Recarbrio","Cilastatin; imipenem; relebactam","RELEBACTAM","Merck & Co.","CHEMBL3301605","A renal dehydropeptidase inhibitor, a penem antibacterial and a beta-lactamase inhibitor","Complicated urinary tract and complicated intra-abdominal infections","urinary tract infection","EFO_0003103","Infectious","P",2019,"",2019,FALSE
"Accrufer","Ferric maltol","FERRIC MALTOL","Shield Therapeutics","CHEMBL4298110","Iron replacement product","Iron deficiency anaemia","iron deficiency anemia","HP_0001891","Hematology","S",2019,"ENSG00000259207; ENSG00000110911",2019,TRUE
"Nubeqa","Darolutamide","DAROLUTAMIDE","Bayer","CHEMBL4297185","Androgen receptor inhibitor","Prostate cancer","prostate cancer","MONDO_0008315","Oncology","P",2019,"ENSG00000169083",2019,TRUE
"Turalio","Pexidartinib","PEXIDARTINIB","Daiichi Sankyo","CHEMBL3813873","CSF1R, KIT and FLT3 inhibitor","Tenosynovial giant cell tumour","Tenosynovial Giant Cell Tumor","EFO_1000562","Oncology","P, O, B",2019,"ENSG00000157404; ENSG00000122025; ENSG00000182578",2019,TRUE
"Wakix","Pitolisant","PITOLISANT","Harmony","CHEMBL462605","H3-receptor antagonist/inverse agonist","Excessive sleepiness due to narcolepsy","narcolepsy","MONDO_0021107","Neurological","P, O",2019,"ENSG00000101180",2019,FALSE
"Pretomanid","Pretomanid","PRETOMANID","Pfizer/Mylan","CHEMBL227875","Antimycobacterial","Tuberculosis","tuberculosis","MONDO_0018076","Infectious","P, O",2019,"",NA,NA
"Rozlytrek","Entrectinib","ENTRECTINIB","Roche","CHEMBL1983268","TRKA, TRKB, TRKC, ROS1 and ALK inhibitor","NTRK fusion-positive solid tumours and ROS1-positive NSCLC","non-small cell lung carcinoma","EFO_0003060","Oncology","P, O, B, A",2019,"ENSG00000171094; ENSG00000148053; ENSG00000047936; ENSG00000198400; ENSG00000140538",2019,TRUE
"Rinvoq","Upadacitinib","UPADACITINIB","AbbVie","CHEMBL3622821","JAK inhibitor","Rheumatoid arthritis","rheumatoid arthritis","EFO_0000685","Immunology","S",2019,"ENSG00000162434; ENSG00000096968; ENSG00000105397; ENSG00000105639",2019,TRUE
"Inrebic","Fedratinib","FEDRATINIB","Celgene/BMS","CHEMBL1287853","JAK2 and FLT3 inhibitor","Myelofibrosis","myelofibrosis","MONDO_0044903","Hematology","P, O",2019,"ENSG00000122025; ENSG00000096968",2019,TRUE
"Xenleta","Lefamulin","LEFAMULIN","Nabriva","CHEMBL3291398","Pleuromutilin antibacterial","CABP","bacterial pneumonia","EFO_1001272","Respiratory","P",2019,"",NA,NA
"Gallium dotatoc Ga-68","Gallium dotatoc Ga-68","GALLIUM DOTATOC GA-68","UIHC PET Imaging Center","CHEMBL4297340","Radioactive diagnostic","Localization of somatostatin receptor-positive neuroendocrine tumours","neuroendocrine neoplasm","EFO_1001901","Oncology","S, O",2019,"",NA,NA
"Nourianz","Istradefylline","ISTRADEFYLLINE","Kyowa Kirin","CHEMBL431770","Adenosine receptor antagonist","Parkinson disease episodes","Parkinson disease","MONDO_0005180","Neurological","S",2019,"ENSG00000128271",2019,TRUE
"Ibsrela","Tenapanor","TENAPANOR","Ardelyx","CHEMBL3304485","NHE3 inhibitor","IBS with constipation","irritable bowel syndrome","EFO_0000555","Gastrointestinal","S",2019,"ENSG00000066230",2019,FALSE
"Aklief","Trifarotene","TRIFAROTENE","Galderma","CHEMBL3707313","Retinoic acid receptor agonist","Acne vulgaris","acne","EFO_0003894","Dermatology","S",2019,"ENSG00000172819",2019,FALSE
"Beovu","Brolucizumab","BROLUCIZUMAB","Novartis","CHEMBL3707357","VEGF inhibitor","Wet age-related macular degeneration","macular degeneration","EFO_0009606","Ophthalmology","S",2019,"ENSG00000112715",2019,TRUE
"Scenesse","Afamelanotide","AFAMELANOTIDE","Clinuvel","CHEMBL441738","Melanocortin 1 receptor agonist","Erythropoietic protoporphyria","erythropoietic protoporphyria","MONDO_0001676","Dermatology","P, O",2019,"ENSG00000258839",2019,TRUE
"Fluorodopa F-18","Fluorodopa F-18","FLUORODOPA F-18","Feinstein Institutes","CHEMBL3400972","Radioactive diagnostic","Diagnosis of parkinsonian syndromes","Parkinson disease","MONDO_0005180","Neurological","S",2019,"",NA,NA
"Reyvow","Lasmiditan","LASMIDITAN","Eli Lilly","CHEMBL3039520","Serotonin (5-HT) 1F receptor agonist","Migraine with or without aura","migraine disorder","MONDO_0005277","Neurological","S",2019,"ENSG00000179097",2019,FALSE
"Trikafta","Tezacaftor; elexacaftor; ivacaftor","TEZACAFTOR","Vertex","CHEMBL3544914","Two CFTR correctors and a CFTR potentiator","Most common gene mutation that causes cystic fibrosis","cystic fibrosis","MONDO_0009061","Metabolic","P, O, B",2019,"ENSG00000001626; ENSG00000001626",2019,TRUE
"Trikafta","Tezacaftor; elexacaftor; ivacaftor","ELEXACAFTOR","Vertex","CHEMBL4298128","Two CFTR correctors and a CFTR potentiator","Most common gene mutation that causes cystic fibrosis","cystic fibrosis","MONDO_0009061","Metabolic","P, O, B",2019,"ENSG00000001626",2019,TRUE
"Trikafta","Tezacaftor; elexacaftor; ivacaftor","IVACAFTOR","Vertex","CHEMBL2010601","Two CFTR correctors and a CFTR potentiator","Most common gene mutation that causes cystic fibrosis","cystic fibrosis","MONDO_0009061","Metabolic","P, O, B",2019,"ENSG00000001626; ENSG00000001626",2019,TRUE
"ExEm Foam","Air polymer-type A","AIR POLYMER-TYPE A","Giskit","CHEMBL4594264","Ultrasound contrast agent","Assess fallopian tube patency in women with known or suspected infertility","infertility","EFO_0000545","Other","S",2019,"",NA,NA
"Reblozyl","Luspatercept","LUSPATERCEPT","Celgene/BMS","CHEMBL3039545","Erythroid maturation agent","Anaemia in beta-thalassaemia","beta thalassemia; anemia","MONDO_0019402; MONDO_0002280","Hematology","P, O",2019,"ENSG00000105329; ENSG00000092969; ENSG00000119699",2019,TRUE
"Fetroja","Cefiderocol","CEFIDEROCOL","Shionogi","CHEMBL3989974","Cephalosporin antibacterial","Complicated urinary tract infections","urinary tract infection","EFO_0003103","Infectious","P",2019,"",NA,NA
"Brukinsa","Zanubrutinib","ZANUBRUTINIB","BeiGene","CHEMBL3936761","BTK inhibitor","Mantle cell lymphoma","mantle cell lymphoma","EFO_1001469","Oncology","P, O, B, A",2019,"ENSG00000010671",2019,TRUE
"Adakveo","Crizanlizumab","CRIZANLIZUMAB","Novartis","CHEMBL4297734","P-selectin blocker","Painful complications of SCD","sickle cell disease and related diseases","MONDO_0017146","Hematology","P, O, B",2019,"ENSG00000174175",2019,FALSE
"Givlaari","Givosiran","GIVOSIRAN","Alnylam","CHEMBL4297760","ALAS1-directed siRNA","Acute hepatic porphyria","acute hepatic porphyria","Orphanet_95157","Metabolic","P, O, B",2019,"ENSG00000023330",2019,FALSE
"Xcopri","Cenobamate","CENOBAMATE","SK Life Science","CHEMBL3989949","Unknown","Partial onset seizures","seizure","HP_0001250","Neurological","S",2019,"ENSG00000168356; ENSG00000196876; ENSG00000186297; ENSG00000185313; ENSG00000144285; ENSG00000151834; ENSG00000153253; ENSG00000011677; ENSG00000187730; ENSG00000109158; ENSG00000022355; ENSG00000166206; ENSG00000183873; ENSG00000182256; ENSG00000136531; ENSG00000145864; ENSG00000169432; ENSG00000268089; ENSG00000145863; ENSG00000094755; ENSG00000163288; ENSG00000113327; ENSG00000136546; ENSG00000102287; ENSG00000163285; ENSG00000007314",2019,TRUE
"Oxbryta","Voxelotor","VOXELOTOR","Global Blood Therapeutics","CHEMBL4101807","Haemoglobin S polymerization inhibitor","SCD (sickle cell disease)","sickle cell anemia","MONDO_0011382","Hematology","P, O, B, A",2019,"ENSG00000206172; ENSG00000244734; ENSG00000188536",2019,TRUE
"Vyondys 53","Golodirsen","GOLODIRSEN","Sarepta","CHEMBL4297762","Exon 53 skipping antisense","Duchenne muscular dystrophy","duchenne muscular dystrophy","MONDO_0010679","Neurological","P, O, A",2019,"ENSG00000198947",2019,TRUE
"Padcev","Enfortumab vedotin","ENFORTUMAB VEDOTIN","Astellas","CHEMBL3301589","Nectin-4-directed ADC","Urothelial cancers","urothelial neoplasm","MONDO_0024337","Oncology","P, B, A",2019,"ENSG00000101162; ENSG00000167552; ENSG00000261456; ENSG00000127824; ENSG00000123416; ENSG00000258947; ENSG00000198033; ENSG00000188229; ENSG00000152086; ENSG00000137267; ENSG00000104833; ENSG00000167553; ENSG00000137285; ENSG00000143217; ENSG00000196230; ENSG00000176014",2019,TRUE
"Tissueblue","Brilliant Blue G","BRILLIANT BLUE G","Dutch Ophthalmic Research","CHEMBL4173394","Brilliant Blue G dye","Staining the internal limiting membrane",NA,NA,"Other","P, O",2019,"",NA,NA
"Dayvigo","Lemborexant","LEMBOREXANT","Eisai","CHEMBL3545367","Orexin receptor antagonist","Insomnia","insomnia","EFO_0004698","Neurological","S",2019,"ENSG00000137252; ENSG00000121764",2019,TRUE
"Enhertu","Trastuzumab deruxtecan","TRASTUZUMAB DERUXTECAN","Daiichi Sankyo/AstraZeneca","CHEMBL4297844","HER2-directed ADC","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Oncology","P, B, A",2019,"ENSG00000141736; ENSG00000198900",2019,TRUE
"Caplyta","Lumateperone","LUMATEPERONE","Intra-Cellular Therapies","CHEMBL3306803","Atypical antipsychotic","Schizophrenia","schizophrenia","MONDO_0005090","Neurological","S",2019,"ENSG00000108576; ENSG00000102468; ENSG00000149295",2019,TRUE
"Ubrelvy","Ubrogepant","UBROGEPANT","Allergan","CHEMBL2364638","CGRP receptor antagonist","Migraine with or without aura","migraine disorder","MONDO_0005277","Neurological","S",2019,"ENSG00000064989",2019,TRUE
"Ayvakit","Avapritinib","AVAPRITINIB","Blueprint Medicines","CHEMBL4204794","PDGFRA, PDGFRA mutants and KIT kinase inhibitor","GIST with PDGFRA exon 18 mutations","gastrointestinal stromal tumor","MONDO_0011719","Oncology","P, O, B",2020,"ENSG00000157404; ENSG00000134853",2020,TRUE
"Tepezza","Teprotumumab","TEPROTUMUMAB","Horizon Therapeutics","CHEMBL1743079","IGF1R-directed mAb","Thyroid eye disease","Graves disease","EFO_0004237","Ophthalmology","P, O, B",2020,"ENSG00000140443",2020,FALSE
"Tazverik","Tazemetostat","TAZEMETOSTAT","Epizyme","CHEMBL3414621","EZH2 inhibitor","Epithelioid sarcoma","epithelioid sarcoma","MONDO_0017387","Oncology","P, O, A",2020,"ENSG00000106462",2020,TRUE
"Pizensy","Lactitol","LACTITOL","Braintree Labs","CHEMBL1661","Osmotic laxative","Chronic idiopathic constipation","Chronic constipation","HP_0012450","Other","S",2020,"",NA,NA
"Vyepti","Eptinezumab","EPTINEZUMAB","Lundbeck","CHEMBL3833320","CGRP-directed mAb","Migraine","migraine disorder","MONDO_0005277","Other","S",2020,"ENSG00000110680; ENSG00000175868",2020,TRUE
"Nexletol","Bempedoic acid","BEMPEDOIC ACID","Esperion Therapeutics","CHEMBL3545313","ACL inhibitor","HeFH or atherosclerotic cardiovascular disease","atherosclerosis; familial hypercholesterolemia","EFO_0003914; EFO_0004911","Cardiovascular","S",2020,"ENSG00000131473",2020,FALSE
"Barhemsys","Amisulpride","AMISULPRIDE","Acacia","CHEMBL243712","Dopamine receptors D2 & D3 antagonist","Nausea and vomiting after surgery","Nausea and vomiting","HP_0002017","Other","S",2020,"ENSG00000164270; ENSG00000157219; ENSG00000158748; ENSG00000151577; ENSG00000166736; ENSG00000186090; ENSG00000178084; ENSG00000102468; ENSG00000149305; ENSG00000179097; ENSG00000135914; ENSG00000178394; ENSG00000168830; ENSG00000149295; ENSG00000147246; ENSG00000186038; ENSG00000148680; ENSG00000135312; ENSG00000179546",2020,FALSE
"Nurtec ODT","Rimegepant","RIMEGEPANT","Biohaven","CHEMBL2178422","CGRP receptor antagonist","Migraine","migraine disorder","MONDO_0005277","Other","S",2020,"ENSG00000064989",2020,TRUE
"Sarclisa","Isatuximab","ISATUXIMAB","Sanofi","CHEMBL3545131","CD38-directed mAb","Multiple myeloma","multiple myeloma","EFO_0001378","Oncology","S, O",2020,"ENSG00000004468",2020,TRUE
"Isturisa","Osilodrostat","OSILODROSTAT","Recordati Rare Diseases","CHEMBL3099695","Cortisol synthesis inhibitor","Cushing disease","Cushing syndrome","EFO_0003099","Endocrine","S, O",2020,"ENSG00000160882",2020,TRUE
"Zeposia","Ozanimod","OZANIMOD","Celgene/Bristol Myers Squibb","CHEMBL3707247","S1P receptor modulator","Multiple sclerosis","multiple sclerosis","MONDO_0005301","Other","S",2020,"ENSG00000170989",2020,TRUE
"Koselugo","Selumetinib","SELUMETINIB","AstraZeneca","CHEMBL1614701","MEK1/2 kinase inhibitor","Neurofibromatosis type 1","neurofibromatosis type 1","MONDO_0018975","Other","P, O, B",2020,"ENSG00000169032; ENSG00000126934",2020,TRUE
"Tukysa","Tucatinib","TUCATINIB","Seagen","CHEMBL3989868","HER2 kinase inhibitor","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Oncology","P, O, B",2020,"ENSG00000141736",2020,TRUE
"Pemazyre","Pemigatinib","PEMIGATINIB","Incyte","CHEMBL4297522","FGFR1-3 kinase inhibitor","Cholangiocarcinoma","cholangiocarcinoma","EFO_0005221","Oncology","P, O, B, A",2020,"ENSG00000066468; ENSG00000068078; ENSG00000077782",2020,TRUE
"Trodelvy","Sacituzumab govitecan","SACITUZUMAB GOVITECAN","Immunomedics/Gilead","CHEMBL3545262","TROP2-directed ADC, with topoisomerase inhibitor","Triple-negative breast cancer (and advanced or metastatic urothelial cancer (mUC)*)","triple-negative breast cancer; urothelial carcinoma","EFO_0005537; EFO_0008528","Oncology","P, B, A",2020,"ENSG00000184292; ENSG00000198900",2020,TRUE
"Ongentys","Opicapone","OPICAPONE","Neurocrine","CHEMBL1089318","COMT inhibitor","Parkinson disease","parkinson disease","MONDO_0005180","Neurological","S",2020,"ENSG00000093010",2020,TRUE
"Tabrecta","Capmatinib","CAPMATINIB","Novartis","CHEMBL3188267","MET kinase inhibitor","NSCLC","non-small cell lung carcinoma","EFO_0003060","Oncology","P, O, B, A",2020,"ENSG00000105976",2020,TRUE
"Retevmo","Selpercatinib","SELPERCATINIB","Eli Lilly/Loxo Oncology","CHEMBL4559134","RET kinase inhibitor","RET fusion-positive NSCLC and thyroid cancer","non-small cell lung carcinoma; thyroid cancer","EFO_0003060; MONDO_0002108","Oncology","P, O, B, A",2020,"ENSG00000108091; ENSG00000165731; ENSG00000170759",2020,TRUE
"Qinlock","Ripretinib","RIPRETINIB","Deciphera","CHEMBL4216467","KIT and PDGFRA kinase inhibitor","GIST","gastrointestinal stromal tumor","MONDO_0011719","Oncology","P, O, B",2020,"ENSG00000134853; ENSG00000157404",2020,TRUE
"Fluoroestradiol F-18","Fluoroestradiol F-18","FLUOROESTRADIOL F-18","Zionexa","CHEMBL4594261","Radioactive diagnostic","Imaging, breast cancer",NA,NA,"Imaging","S",2020,"",NA,NA
"Artesunate","Artesunate","ARTESUNATE","Amivas","CHEMBL361497","Artemisinin antimalarial","Severe malaria","malaria","EFO_0001068","Infectious","P, O, B",2020,"",NA,NA
"Flortaucipir F-18","Flortaucipir F-18","FLORTAUCIPIR F-18","Eli Lilly","CHEMBL3545253","Radioactive diagnostic","Imaging, tau in Alzheimer disease",NA,NA,"Imaging","P",2020,"",NA,NA
"Uplizna","Inebilizumab","INEBILIZUMAB","Viela Bio","CHEMBL2109334","CD19-directed mAb","NMOSD","neuromyelitis optica","EFO_0004256","Neurological","S, O, B",2020,"ENSG00000177455",2020,FALSE
"Zepzelca","Lurbinectedin","LURBINECTEDIN","Jazz","CHEMBL4297516","Alkylating drug","Small-cell lung cancer","small cell lung carcinoma","EFO_0000702","Oncology","P, O, A",2020,"",NA,NA
"Dojolvi","Triheptanoin","TRIHEPTANOIN","Ultragenyx","CHEMBL4297585","Medium-chain triglyceride","LC-FAODs","inherited fatty acid metabolism disorder","MONDO_0037858","Metabolic","S, O",2020,"",NA,NA
"Rukobia","Fostemsavir","FOSTEMSAVIR","ViiV Healthcare","CHEMBL3301594","Attachment inhibitor","HIV","hiv infection","EFO_0000764","Infectious","P, B",2020,"",NA,NA
"Byfavo","Remimazolam","REMIMAZOLAM","Acacia","CHEMBL4297526","Benzodiazepine","Procedural sedation","sedation","EFO_0009868","Other","S",2020,"ENSG00000102287; ENSG00000163288; ENSG00000186297; ENSG00000145864; ENSG00000113327; ENSG00000011677; ENSG00000094755; ENSG00000163285; ENSG00000151834; ENSG00000109158; ENSG00000268089; ENSG00000187730; ENSG00000182256; ENSG00000022355; ENSG00000145863; ENSG00000166206",2020,TRUE
"Inqovi","Cedazuridine; decitabine","CEDAZURIDINE","Otsuka","CHEMBL3237547","Cytidine deaminase inhibitor; nucleoside metabolic inhibitor","Myelodysplastic syndromes","myelodysplastic syndrome","EFO_0000198","Hematology","P, O",2020,"ENSG00000158825",2020,TRUE
"Inqovi","Cedazuridine; decitabine","DECITABINE","Otsuka","CHEMBL1201129","Cytidine deaminase inhibitor; nucleoside metabolic inhibitor","Myelodysplastic syndromes","myelodysplastic syndrome","EFO_0000198","Hematology","P, O",2020,"ENSG00000130816; ENSG00000119772",2020,TRUE
"Xeglyze","Abametapir","ABAMETAPIR","Dr Reddy‚Äö√Ñ√¥s","CHEMBL2205807","Metalloproteinase inhibitor","Head lice","lice infestation","MONDO_0003472","Dermatology","S",2020,"",NA,NA
"Monjuvi","Tafasitamab","TAFASITAMAB","MorphoSys","CHEMBL4298047","CD19-directed mAb","DLBCL","diffuse large b-cell lymphoma","EFO_0000403","Oncology","P, O, B, A",2020,"ENSG00000177455",2020,TRUE
"Blenrep","Belantamab mafodotin","BELANTAMAB MAFODOTIN","GlaxoSmithKline","CHEMBL4298209","BCMA-directed ADC, with microtubule inhibitor","Multiple myeloma","multiple myeloma","EFO_0001378","Oncology","P, O, B, A",2020,"ENSG00000048462; ENSG00000152086; ENSG00000167553; ENSG00000188229; ENSG00000137267; ENSG00000176014; ENSG00000261456; ENSG00000127824; ENSG00000123416; ENSG00000137285; ENSG00000258947; ENSG00000167552; ENSG00000198033; ENSG00000196230; ENSG00000104833; ENSG00000101162",2020,TRUE
"Lampit","Nifurtimox","NIFURTIMOX","Bayer","CHEMBL290960","Nitrofuran antiprotozoal","Chagas disease","chagas disease","MONDO_0001444","Infectious","P, O, A",2020,"",NA,NA
"Olinvyk","Oliceridine","OLICERIDINE","Trevena","CHEMBL2443262","Opioid receptor agonist","Acute pain","pain","EFO_0003843","Other","S",2020,"ENSG00000112038",2020,FALSE
"Evrysdi","Risdiplam","RISDIPLAM","Roche/Genentech","CHEMBL4297528","SMN2 splicing modifier","Spinal muscular atrophy","spinal muscular atrophy","EFO_0008525","Neurological","P, O",2020,"ENSG00000205571",2020,TRUE
"Viltepso","Viltolarsen","VILTOLARSEN","Nippon Shinyaku","CHEMBL4298062","Dystrophin splicing modifier","Duchenne muscular dystrophy","duchenne muscular dystrophy","MONDO_0010679","Neurological","P, O, A",2020,"ENSG00000198947",2020,TRUE
"Enspryng","Satralizumab","SATRALIZUMAB","Roche/Genentech","CHEMBL3833307","IL-6R-directed mAb","NMOSD","neuromyelitis optica","EFO_0004256","Neurology","S, O, B",2020,"ENSG00000160712; ENSG00000134352",2020,TRUE
"Winlevi","Clascoterone","CLASCOTERONE","Cassiopea SpA","CHEMBL3590187","Androgen receptor inhibitor","Acne vulgaris","acne","EFO_0003894","Dermatology","S",2020,"ENSG00000169083",2020,TRUE
"Sogroya","Somapacitan","SOMAPACITAN","Novo Nordisk","CHEMBL3707290","Growth hormone analogue","Growth hormone deficiency","short stature due to partial GHR deficiency","MONDO_0011420","Endocrine","S",2020,"ENSG00000112964",2020,TRUE
"Copper dotatate Cu-64","Copper dotatate Cu-64","COPPER DOTATATE CU-64","Radiomedix","CHEMBL4297339","Radioactive diagnostic","Imaging, cancer",NA,NA,"Imaging","P, O",2020,"",NA,NA
"Gavreto","Pralsetinib","PRALSETINIB","Blueprint Medicines/Roche","CHEMBL4582651","RET kinase inhibitor","RET fusion-positive NSCLC","non-small cell lung carcinoma","EFO_0003060","Oncology","P, O, B, A",2020,"ENSG00000108091; ENSG00000170759; ENSG00000165731",2020,TRUE
"Inmazeb","Atoltivimab; odesivimab; maftivimab","ATOLTIVIMAB","Regeneron","CHEMBL4298183","Cocktail of Ebola glycoprotein-directed mAbs","Ebola virus","Ebola hemorrhagic fever","EFO_0007243","Infectious","P, O, B",2020,"",NA,NA
"Inmazeb","Atoltivimab; odesivimab; maftivimab","ODESIVIMAB","Regeneron","CHEMBL4298188","Cocktail of Ebola glycoprotein-directed mAbs","Ebola virus","Ebola hemorrhagic fever","EFO_0007243","Infectious","P, O, B",2020,"",NA,NA
"Inmazeb","Atoltivimab; odesivimab; maftivimab","MAFTIVIMAB","Regeneron","CHEMBL4298184","Cocktail of Ebola glycoprotein-directed mAbs","Ebola virus","Ebola hemorrhagic fever","EFO_0007243","Infectious","P, O, B",2020,"",NA,NA
"Veklury","Remdesivir","REMDESIVIR","Gilead","CHEMBL4065616","Nucleotide analogue RNA polymerase inhibitor","COVID-19","covid-19","MONDO_0100096","Infectious","P",2020,"",NA,NA
"Zokinvy","Lonafarnib","LONAFARNIB","Eiger","CHEMBL298734","Farnesyltransferase inhibitor","HGPS","hutchinson-gilford progeria syndrome","MONDO_0008310","Other","P, O, B",2020,"ENSG00000257365; ENSG00000168522",2020,FALSE
"Oxlumo","Lumasiran","LUMASIRAN","Alnylam","CHEMBL4297779","HAO1-directed siRNA","Hyperoxaluria type 1","primary hyperoxaluria type 1","MONDO_0009823","Nephrology","P, O, B",2020,"ENSG00000101323",2020,FALSE
"Danyelza","Naxitamab","NAXITAMAB","Y-mAbs Therapeutics","CHEMBL4297984","GD2-directed mAb","High-risk neuroblastoma","neuroblastoma","EFO_0000621","Oncology","P, O, B, A",2020,"",NA,NA
"Imcivree","Setmelanotide","SETMELANOTIDE","Rhythm","CHEMBL3301624","Melanocortin receptor 4 agonist","Rare genetic diseases of obesity","Bardet-Biedl syndrome","MONDO_0015229","Other","P, O, B",2020,"ENSG00000166603",2020,TRUE
"PSMA-11 Ga-68","PSMA-11 Ga-68","PSMA-11 GA-68","UCLA","CHEMBL4297335","Radioactive diagnostic","Imaging, prostate cancer",NA,NA,"Imaging","S",2020,"",NA,NA
"Orladeyo","Berotralstat","BEROTRALSTAT","BioCryst","CHEMBL4594271","Plasma kallikrein inhibitor","Hereditary angioedema","hereditary angioedema","MONDO_0019623","Immunology","S, O",2020,"ENSG00000164344",2020,FALSE
"Klisyri","Tirbanibulin","TIRBANIBULIN","Athenex","CHEMBL571546","Microtubule inhibitor","Actinic keratosis","actinic keratosis","EFO_0002496","Dermatology","S",2020,"ENSG00000197122",2020,TRUE
"Margenza","Margetuximab","MARGETUXIMAB","MacroGenics","CHEMBL2364649","HER2-directed mAb","HER2-positive breast cancer","HER2 Positive Breast Carcinoma","EFO_1000294","Oncology","S",2020,"ENSG00000141736",2020,TRUE
"Orgovyx","Relugolix","RELUGOLIX","Myovant Sciences","CHEMBL1800159","GnRH receptor antagonist","Prostate cancer","prostate cancer","MONDO_0008315","Oncology","P",2020,"ENSG00000109163",2020,TRUE
"Ebanga","Ansuvimab","ANSUVIMAB","Ridgeback","CHEMBL4594388","Ebola glycoprotein-directed mAb","Ebola virus","Ebola hemorrhagic fever","EFO_0007243","Infectious","P, O, B",2020,"",NA,NA
"Gemtesa","Vibegron","VIBEGRON","Urovant Sciences","CHEMBL2107826","Beta-3 adrenergic receptor agonist","Overactive bladder","overactive bladder","EFO_1000781","Other","S",2020,"ENSG00000188778",2020,FALSE
"Verquvo","Vericiguat","Vericiguat","Merck & Co./Bayer","CHEMBL4066936","sGC stimulator","Chronic heart failure","coronary artery disease","EFO_0001645","Cardiovascular","P",2021,"ENSG00000123201; ENSG00000061918; ENSG00000152402; ENSG00000164116",2021,TRUE
"Cabenuva Kit","Cabotegravir; rilpivirine","Cabotegravir","ViiV","CHEMBL2403238","INSTI and an NNRTI","HIV-1 infection",NA,NA,"Infectious","P",2021,"",NA,NA
"Cabenuva Kit","Cabotegravir; rilpivirine","rilpivirine","ViiV","CHEMBL175691","INSTI and an NNRTI","HIV-1 infection",NA,NA,"Infectious","P",2021,"",NA,NA
"Lupkynis","Voclosporin","Voclosporin","Aurinia","CHEMBL2218919","Calcineurin inhibitor","Lupus nephritis","lupus nephritis","EFO_0005761","Nephrology","P",2021,"ENSG00000138814",2021,TRUE
"Tepmetko","Tepotinib","Tepotinib","EMD Serono","CHEMBL3402762","MET kinase inhibitor","NSCLC","non-small cell lung carcinoma","EFO_0003060","Oncology","P, O, A",2021,"ENSG00000105976",2021,TRUE
"Ukoniq","Umbralisib","Umbralisib","TG Therapeutics","CHEMBL3948730","PI3Kdelta and CK1epsilon inhibitor","MZL, follicular lymphoma","MZL; follicular lymphoma","EFO_1000630; MONDO_0018906","Oncology","P, O, B, A",2021,"ENSG00000097007; ENSG00000171608; ENSG00000213923",2021,TRUE
"Evkeeza","Evinacumab","Evinacumab","Regeneron","CHEMBL3545191","ANGPTL3-targeted mAb","HoFH","homozygous familial hypercholesterolemia","MONDO_0018328","Metabolic","P, O, B",2021,"ENSG00000132855",2021,TRUE
"Cosela","Trilaciclib","Trilaciclib","G1 Therapeutics","CHEMBL3894860","CDK4 and CDK6 kinase inhibitor","Chemotherapy-induced myelosuppression","myelosuppression; small cell lung carcinoma","EFO_0007053; EFO_0000702","Oncology","P, B",2021,"ENSG00000135446; ENSG00000105810",2021,TRUE
"Amondys 45","Casimersen","Casimersen","Sarepta","CHEMBL4297566","Exon 45-skipping ASO","DMD","Duchenne muscular dystrophy","MONDO_0010679","Other","P, O, A",2021,"ENSG00000198947",2021,TRUE
"Nulibry","Fosdenopterin","Fosdenopterin","BridgeBio","CHEMBL2338675","cPMP","MoCD type A","sulfite oxidase deficiency due to molybdenum cofactor deficiency","MONDO_0020480","Other","P, O, B",2021,"ENSG00000164172",2021,TRUE
"Pepaxto","Melphalan flufenamide","Melphalan flufenamide","Oncopeptides","CHEMBL4303060","Peptide-conjugated alkylating drug","Multiple myeloma","multiple myeloma","EFO_0001378","Oncology","P, O, A",2021,"",NA,NA
"Azstarys","Dexmethylphenidate; serdexmethylphenidate","Dexmethylphenidate","Commave Therapeutics","CHEMBL827","CNS stimulant","ADHD","attention deficit hyperactivity disorder","EFO_0003888","Psychiatric","S",2021,"ENSG00000103546; ENSG00000142319",2021,TRUE
"Azstarys","Dexmethylphenidate; serdexmethylphenidate","serdexmethylphenidate","Commave Therapeutics","CHEMBL4301162","CNS stimulant","ADHD","attention deficit hyperactivity disorder","EFO_0003888","Psychiatric","S",2021,"ENSG00000103546; ENSG00000142319",2021,TRUE
"Fotivda","Tivozanib","Tivozanib","Aveo","CHEMBL1289494","VEGFR kinase inhibitor","Renal cell carcinoma","renal cell carcinoma","EFO_0000681","Oncology","S",2021,"ENSG00000102755; ENSG00000128052; ENSG00000157404; ENSG00000113721; ENSG00000037280",2021,TRUE
"Ponvory","Ponesimod","Ponesimod","J&J","CHEMBL1096146","S1P receptor modulator","Relapsing multiple sclerosis","multiple sclerosis","MONDO_0005301","Other","S",2021,"ENSG00000170989",2021,TRUE
"Zegalogue","Dasiglucagon","Dasiglucagon","Zealand Pharma","CHEMBL4297741","Glucagon receptor agonist","Severe hypoglycaemia","GCGR-related hyperglucagonemia","EFO_0001360","Metabolic","S",2021,"ENSG00000215644",2021,TRUE
"Qelbree","Viloxazine","Viloxazine","Supernus","CHEMBL306700","SNRI","ADHD","attention deficit hyperactivity disorder","EFO_0003888","Psychiatric","S",2021,"ENSG00000103546",2021,FALSE
"Nextstellis","Drospirenone; estetrol","Drospirenone","Mayne Pharma","CHEMBL1509","Spironolactone and oestrogen analogues","To prevent pregnancy",NA,NA,"Reproductive","S",2021,"ENSG00000151623; ENSG00000082175",2021,FALSE
"Nextstellis","Drospirenone; estetrol","estetrol","Mayne Pharma","CHEMBL1230314","Spironolactone and oestrogen analogues","To prevent pregnancy",NA,NA,"Reproductive","S",2021,"ENSG00000091831; ENSG00000140009",2021,FALSE
"Jemperli","Dostarlimab","Dostarlimab","GlaxoSmithKline","CHEMBL4298124","PD1-targeted mAb","Endometrial cancer","endometrial cancer","MONDO_0011962","Oncology","P, B, A",2021,"ENSG00000188389",2021,TRUE
"Zynlonta","Loncastuximab tesirine","Loncastuximab tesirine","ADC Therapeutics","CHEMBL4297778","CD19-targeted ADC","B-cell lymphoma","B-cell non-Hodgkins lymphoma","EFO_1001938","Oncology","P, O, A",2021,"ENSG00000177455",2021,TRUE
"Empaveli","Pegcetacoplan","Pegcetacoplan","Apellis","CHEMBL4298211","Complement protein C3 inhibitor","PNH","paroxysmal nocturnal hemoglobinuria","MONDO_0100244","Other","P, O",2021,"ENSG00000125730",2021,TRUE
"Rybrevant","Amivantamab","Amivantamab","J&J","CHEMBL4297774","EGFRxMETR bispecific antibody","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Oncology","P, B, A",2021,"ENSG00000146648; ENSG00000105976",2021,TRUE
"Pylarify","Piflufolastat F-18","Piflufolastat F-18","Progenics","CHEMBL4297334","Radiolabelled PSMA imaging agent","Prostate cancer imaging",NA,NA,"Imaging","P",2021,"",NA,NA
"Truseltiq","Infigratinib","Infigratinib","BridgeBio","CHEMBL1852688","FGFR2 kinase inhibitor","FGFR2-mutated bile duct cancer","bile duct cancer","MONDO_0003059","Oncology","P, O, A",2021,"ENSG00000160867; ENSG00000068078; ENSG00000066468; ENSG00000077782",2021,TRUE
"Lumakras","Sotorasib","Sotorasib","Amgen","CHEMBL4535757","KRAS-G12C inhibitor","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Oncology","P, O, B, A",2021,"ENSG00000133703",2021,TRUE
"Lybalvi","Olanzapine; samidorphan","samidorphan","Alkermes","CHEMBL426084","Atypical antipsychotic and opioid antagonist","Schizophrenia and bipolar I disorder","Schizophrenia; bipolar I disorder","MONDO_0005090; EFO_0009963","Psychiatric","S",2021,"ENSG00000112038; ENSG00000082556; ENSG00000116329",2021,TRUE
"Lybalvi","Olanzapine; samidorphan","Olanzapine","Alkermes","CHEMBL715","Atypical antipsychotic and opioid antagonist","Schizophrenia and bipolar I disorder","Schizophrenia; bipolar I disorder","MONDO_0005090; EFO_0009963","Psychiatric","S",2021,"ENSG00000147246; ENSG00000151577; ENSG00000102468; ENSG00000069696; ENSG00000149295",2021,TRUE
"Brexafemme","Ibrexafungerp","Ibrexafungerp","Scynexis","CHEMBL4297513","Triterpenoid antifungal","Vulvovaginal candidiasis",NA,NA,"Infectious","P",2021,"",NA,NA
"Aduhelm","Aducanumab","Aducanumab","Biogen/Eisai","CHEMBL3039540","Amyloid-beta-targeted mAb","Alzheimers disease","Alzheimers disease","MONDO_0004975","Other","P, A",2021,"ENSG00000142192",2021,TRUE
"Rylaze","Asparaginase erwinia chrysanthemi","Asparaginase erwinia chrysanthemi","Jazz","CHEMBL1863514","Recombinant asparagine-specific enzyme","ALL and LBL, in patients allergic to E. coli-derived products","acute lymphoblastic leukemia; lymphoblastic lymphoma","EFO_0000220; MONDO_0000873","Oncology","S, O",2021,"ENSG00000166183",2021,FALSE
"Kerendia","Finerenone","Finerenone","Bayer","CHEMBL2181927","Non-steroidal MR antagonist","CKD with type 2 diabetes","chronic kidney disease","EFO_0003884","Other","P",2021,"ENSG00000151623",2021,TRUE
"Fexinidazole","Fexinidazole","Fexinidazole","Sanofi/DNDi","CHEMBL1631694","Nitroimidazole antimicrobial","Sleeping sickness",NA,NA,"Infectious","P, O",2021,"",NA,NA
"Rezurock","Belumosudil","Belumosudil","Kadmon","CHEMBL2005186","ROCK2 kinase inhibitor","Chronic GVHD","graft versus host disease","MONDO_0013730","Other","P, O, B",2021,"ENSG00000134318; ENSG00000067900",2021,FALSE
"Bylvay","Odevixibat","Odevixibat","Albireo","CHEMBL4297588","IBAT inhibitor","Pruritus in PFIC","familial intrahepatic cholestasis","MONDO_0017290","Other","P, O",2021,"ENSG00000125255",2021,TRUE
"Saphnelo","Anifrolumab","Anifrolumab","AstraZeneca","CHEMBL2364653","IFNAR-targeted mAb","SLE","systemic lupus erythematosus","MONDO_0007915","Other","S",2021,"ENSG00000142166",2021,TRUE
"Nexviazyme","Avalglucosidase alfa","Avalglucosidase alfa","Sanofi","CHEMBL4594320","Recombinant alpha-glucosidase","Pompe disease","glycogen storage disease II","MONDO_0009290","Other","P, O, B",2021,"ENSG00000171298",2021,TRUE
"Welireg","Belzutifan","Belzutifan","Merck & Co.","CHEMBL4585668","HIF-2alpha inhibitor","von Hippel-Lindau disease","von Hippel-Lindau disease","MONDO_0008667","Oncology","P, O",2021,"ENSG00000116016",2021,TRUE
"Korsuva","Difelikefalin","Difelikefalin","Cara Therapeutics","CHEMBL3989915","kappa-Opioid receptor agonist","Pruritus associated with CKD","chronic kidney disease","EFO_0003884","Other","P, B",2021,"ENSG00000082556",2021,FALSE
"Skytrofa","Lonapegsomatropin","Lonapegsomatropin","Ascendis Pharma","CHEMBL4298185","PEGylated human growth hormone","Growth failure due to GHD","Growth delay","HP_0001510","Other","S, O",2021,"ENSG00000112964",2021,TRUE
"Exkivity","Mobocertinib","Mobocertinib","Takeda","CHEMBL4650319","EGFR kinase inhibitor","EGFR exon 20-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Oncology","P, O, B, A",2021,"ENSG00000146648",2021,TRUE
"Tivdak","Tisotumab vedotin","Tisotumab vedotin","Seagen/Genmab","CHEMBL4297841","Tissue-factor-directed ADC","Cervical cancer","cervical cancer","MONDO_0002974","Oncology","P, A",2021,"ENSG00000167552; ENSG00000258947; ENSG00000137267; ENSG00000188229; ENSG00000176014; ENSG00000261456; ENSG00000123416; ENSG00000198033; ENSG00000196230; ENSG00000167553; ENSG00000152086; ENSG00000117525; ENSG00000104833; ENSG00000137285; ENSG00000101162; ENSG00000127824",2021,TRUE
"Qulipta","Atogepant","Atogepant","AbbVie","CHEMBL3991065","CGRP receptor antagonist","Episodic migraine","migraine disorder","MONDO_0005277","Other","S",2021,"ENSG00000064989",2021,TRUE
"Livmarli","Maralixibat","Maralixibat","Mirum","CHEMBL363392","IBAT inhibitor","Pruritus in Alagille syndrome","Alagille syndrome","MONDO_0007318","Other","P, O, B",2021,"ENSG00000125255",2021,TRUE
"Tavneos","Avacopan","Avacopan","ChemoCentryx","CHEMBL3989871","Complement 5a receptor antagonist","ANCA-associated vasculitis","Anti-neutrophil cytoplasmic antibody-associated vasculitis","MONDO_0015492","Cardiovascular","S, O",2021,"ENSG00000197405",2021,FALSE
"Scemblix","Asciminib","Asciminib","Novartis","CHEMBL4208229","ABL/BCR-ABL1  kinase inhibitor","Ph+ CML","Blast Phase Chronic Myelogenous Leukemia; BCR-ABL1 Positive","EFO_1000131","Oncology","P, O, B, A",2021,"ENSG00000097007",2021,TRUE
"Besremi","Ropeginterferon alfa-2b","Ropeginterferon alfa-2b","Pharmaessentia","CHEMBL4297819","PEGylated interferon alpha-2b","Polycythaemia vera","polycythemia vera","EFO_0002429","Oncology","S, O",2021,"ENSG00000142166; ENSG00000159110",2021,TRUE
"Voxzogo","Vosoritide","Vosoritide","Biomarin","CHEMBL3707276","CNP analogue","Achondroplasia","achondroplasia","MONDO_0007037","Other","P, O, A",2021,"ENSG00000159899",2021,TRUE
"Livtencity","Maribavir","Maribavir","Takeda","CHEMBL515408","CMV pUL97 kinase inhibitor","Post-transplant CMV infection",NA,NA,"Infectious","P, O, B",2021,"",NA,NA
"Cytalux","Pafolacianine","Pafolacianine","On Target Labs","CHEMBL4297412","Fluorescent FR imaging agent","Ovarian cancer imaging",NA,NA,"Imaging","P, O",2021,"",NA,NA
"Vyvgart","Efgartigimod alfa","Efgartigimod alfa","Argenx","CHEMBL4297551","FcRn-binding Fc fragment","Myasthenia gravis","Myasthenia gravis","EFO_0004991","Other","S, O",2021,"ENSG00000104870",2021,FALSE
"Tezspire","Tezepelumab","Tezepelumab","Astrazeneca/Amgen","CHEMBL3707229","TSLP-targeted mAb","Severe asthma","asthma","MONDO_0004979","Respiratory","P",2021,"ENSG00000145777",2021,TRUE
"Leqvio","Inclisiran","Inclisiran","Novartis/Alnylam","CHEMBL3990033","PCSK9-targeted siRNA","HeFH or ASCVD","coronary atherosclerosis","MONDO_0021661","Cardiovascular","S",2021,"ENSG00000169174",2021,TRUE
"Adbry","Tralokinumab","Tralokinumab","LEO Pharma","CHEMBL1743081","IL-13-targeted mAb","Atopic dermatitis","atopic eczema","EFO_0000274","Dermatology","S",2021,"ENSG00000169194",2021,TRUE
"Cibinqo","Abrocitinib","Abrocitinib","Pfizer","CHEMBL3655081","JAK inhibitor","Atopic dermatitis","atopic eczema, Eczema","EFO_0000274; HP_0000964","Dermatology","P, B",2022,"ENSG00000162434; ENSG00000166888",2022,TRUE
"Krazati","Adagrasib","Adagrasib","Mirati","CHEMBL4594350","KRAS-G12C inhibitor","KRASG12C-mutated NSCLC","non-small cell lung carcinoma","EFO_0003060","Oncology","S, O, B, A",2022,"ENSG00000133703",2022,TRUE
"NexoBrid","Anacaulase","Anacaulase","Mediwound",NA,"Proteolytic enzymes from pineapple plants","Eschar removal after thermal burns",NA,NA,"Other","S, O",2022,"",NA,NA
"Quviviq","Daridorexant","Daridorexant","Idorsia","CHEMBL4297590","Orexin receptor antagonist","Insomnia","insomnia","EFO_0004698","Other","S",2022,"ENSG00000137252; ENSG00000121764",2022,TRUE
"Daxxify","DaxibotulinumtoxinA","DaxibotulinumtoxinA","Revance","CHEMBL3707359","Botulinum toxin","Glabellar lines","Facial wrinkling","HP_0009762","Other","S",2022,"ENSG00000132639",2022,FALSE
"Sotyktu","Deucravacitinib","Deucravacitinib","Bristol Myers Squibb","CHEMBL4435170","TYK2 inhibitor","Plaque psoriasis","psoriasis vulgaris","EFO_1001494","Dermatology","S",2022,"ENSG00000105397",2022,TRUE
"Rolvedon","Eflapegrastim","Eflapegrastim","Spectrum","CHEMBL3833384","Leukocyte growth factor","Incidence of infection in non-myeloid malignancies, with myelosuppressive drugs","infection","EFO_0000544","Infectious","S",2022,"ENSG00000119535",2022,TRUE
"Vabysmo","Faricimab","Faricimab","Roche/Genentech","CHEMBL4297750","VEGF _ ANG2 bispecific antibody","nAMD and DME","age-related macular degeneration","EFO_0001365","Ophthalmology","S",2022,"ENSG00000112715; ENSG00000091879",2022,TRUE
"Lytgobi","Futibatinib","Futibatinib","Taiho Oncology","CHEMBL3701238","FGFR kinase inhibitor","FGFR2-aberrant intrahepatic cholangiocarcinoma","intrahepatic cholangiocarcinoma","EFO_1001961","Oncology","P, O, B, A",2022,"ENSG00000068078; ENSG00000077782; ENSG00000160867; ENSG00000066468",2022,TRUE
"Elucirem","Gadopiclenol","Gadopiclenol","Guerbet","CHEMBL4297634","Gadolinium-based contrast agent","Lesions with abnormal vascularity",NA,NA,"Imaging","P",2022,"",NA,NA
"Ztalmy","Ganaxolone","Ganaxolone","Marinus","CHEMBL1568698","GABAA receptor positive allosteric modulator","Seizures associated with CDD","Epileptic encephalopathy","HP_0200134","Other","P, O",2022,"ENSG00000094755; ENSG00000163288; ENSG00000102287; ENSG00000166206; ENSG00000145863; ENSG00000022355; ENSG00000113327; ENSG00000187730; ENSG00000011677; ENSG00000268089; ENSG00000145864; ENSG00000151834; ENSG00000186297; ENSG00000182256; ENSG00000109158; ENSG00000163285",2022,TRUE
"Sunlenca","Lenacapavir","Lenacapavir","Gilead","CHEMBL4594438","HIV-1 capsid inhibitor","HIV-1 infection","HIV-1 infection","EFO_0000180","Infectious","P, B",2022,"",NA,NA
"Pluvicto","Lutetium Lu-177 vipivotide tetraxetan","Lutetium Lu-177 vipivotide tetraxetan","Novartis","CHEMBL4594406","PSMA-binding radioligand therapeutic agent","PSMA-positive prostate cancer","prostate carcinoma","EFO_0001663","Oncology","P, B",2022,"ENSG00000142515",2022,TRUE
"Camzyos","Mavacamten","Mavacamten","Bristol Myers Squibb","CHEMBL4297517","Cardiac myosin inhibitor","Classes of obstructive HCM (Hypertrophic Obstructive Cardiomyopathy)","hypertrophic cardiomyopathy","EFO_0000538","Cardiovascular","S, O, B",2022,"ENSG00000092054",2022,TRUE
"Elahere","Mirvetuximab soravtansine","Mirvetuximab soravtansine","ImmunoGen","CHEMBL3545132","FR_-targeted antibody-drug conjugate","Ovarian cancer","ovarian carcinoma","EFO_0001075","Oncology","P, O, A",2022,"ENSG00000127824; ENSG00000152086; ENSG00000110195; ENSG00000261456; ENSG00000101162; ENSG00000188229; ENSG00000104833; ENSG00000258947; ENSG00000123416; ENSG00000198033; ENSG00000167553; ENSG00000137285; ENSG00000167552; ENSG00000176014; ENSG00000137267; ENSG00000196230",2022,TRUE
"Pyrukynd","Mitapivat","Mitapivat","Agios","CHEMBL4299940","Pyruvate kinase activator","Haemolytic anaemia due to PK deficiency","hemolytic anemia","EFO_0005558","Other","P, O",2022,"ENSG00000143627",2022,TRUE
"Lunsumio","Mosunetuzumab","Mosunetuzumab","Roche/Genentech","CHEMBL4297788","CD20 _ CD3 bispecific antibody","Follicular lymphoma","follicular lymphoma","MONDO_0018906","Oncology","P, O, B, A",2022,"ENSG00000167286; ENSG00000156738; ENSG00000198851; ENSG00000160654",2022,TRUE
"Xenpozyme","Olipudase alfa","Olipudase alfa","Sanofi/Genzyme","CHEMBL3707358","Acid sphingomyelinase ERT","Acid sphingomyelinase deficiency","acid sphingomyelinase deficiency","MONDO_0100464","Other","P, O, B",2022,"ENSG00000166311",2022,TRUE
"Rezlidhia","Olutasidenib","Olutasidenib","Rigel/Forma","CHEMBL4297610","IDH1 inhibitor","IDH1-mutated AML","acute myeloid leukemia","EFO_0000222","Oncology","S, O",2022,"ENSG00000138413",2022,TRUE
"Omlonti","Omidenepag isopropyl","Omidenepag isopropyl","Santen","CHEMBL4297666","Prostaglandin E2 receptor agonist","Intraocular pressure in open-angle glaucoma or ocular hypertension","ocular hypertension, open-angle glaucoma","EFO_1001069; EFO_0004190","Ophthalmology","S",2022,"ENSG00000125384",2022,FALSE
"Vivjoa","Oteseconazole","Oteseconazole","Mycovia","CHEMBL3311228","Azole antifungal","Vulvovaginal candidiasis","vulvovaginal candidiasis","EFO_0007543","Infectious","P",2022,"",NA,NA
"Vonjo","Pacritinib","Pacritinib","CTI Biopharma","CHEMBL2035187","JAK2 inhibitor","Myelofibrosis","myelofibrosis","MONDO_0044903","Oncology","P, O, A",2022,"ENSG00000096968; ENSG00000122025",2022,TRUE
"Opdualag","Relatlimab; nivolumab","Relatlimab","Bristol Myers Squibb","CHEMBL3990044","LAG3-targeted mAb plus PD1-targeted mAb","Melanoma","melanoma","EFO_0000756","Oncology","P, O",2022,"ENSG00000089692",2022,TRUE
"Opdualag","Relatlimab; nivolumab","nivolumab","Bristol Myers Squibb","CHEMBL2108738","LAG3-targeted mAb plus PD1-targeted mAb","Melanoma","melanoma","EFO_0000756","Oncology","P, O",2022,"ENSG00000188389",2022,TRUE
"Relyvrio","Sodium phenylbutyrate; taurursodiol","Sodium phenylbutyrate","Amylyx","CHEMBL1746","Mechanism unknown","Amyotrophic lateral sclerosis","amyotrophic lateral sclerosis","MONDO_0004976","Other","P, O",2022,"",NA,NA
"Relyvrio","Sodium phenylbutyrate; taurursodiol","taurursodiol","Amylyx","CHEMBL272427","Mechanism unknown","Amyotrophic lateral sclerosis","amyotrophic lateral sclerosis","MONDO_0004976","Other","P, O",2022,"",NA,NA
"Spevigo","Spesolimab","Spesolimab","Boehringer Ingelheim","CHEMBL4297911","IL-36R-targeted mAb","Generalized pustular psoriasis flares","psoriasis 14, pustular","MONDO_0013626","Dermatology","P, O, B",2022,"ENSG00000115598; ENSG00000196083; ENSG00000136695",2022,TRUE
"Enjaymo","Sutimlimab","Sutimlimab","Bioverativ","CHEMBL4297832","C1s-targeted mAb","RBC transfusion due to haemolysis in CAD (cold agglutinin disease)","Anemia, Hemolytic, Autoimmune","EFO_1001264","Autoimmune","P, O, B",2022,"ENSG00000182326",2022,FALSE
"Vtama","Tapinarof","Tapinarof","Dermavant","CHEMBL259571","Aryl hydrocarbon receptor agonist","Plaque psoriasis","psoriasis vulgaris","EFO_1001494","Dermatology","S",2022,"ENSG00000106546",2022,FALSE
"Kimmtrak","Tebentafusp","Tebentafusp","Immunocore","CHEMBL4297990","gp100 peptide HLA _ CD3 bispecific T-cell engager","Uveal melanoma","Uveal Melanoma","EFO_1000616","Oncology","P, O, B",2022,"ENSG00000185664",2022,FALSE
"Tecvayli","Teclistamab","Teclistamab","J&J","CHEMBL4594505","BCMA _ CD3 bispecific antibody","Multiple myeloma","multiple myeloma","EFO_0001378","Oncology","P, O, B, A",2022,"ENSG00000160654; ENSG00000198851; ENSG00000048462; ENSG00000167286",2022,TRUE
"Tzield","Teplizumab","Teplizumab","Provention Bio","CHEMBL1743078","CD3-targeted antibody","Delay onset of type 1 diabetes","type 1 diabetes mellitus","MONDO_0005147","Autoimmune","P, B",2022,"ENSG00000198851; ENSG00000081237; ENSG00000198821",2022,TRUE
"Terlivaz","Terlipressin","Terlipressin","Mallinckrodt","CHEMBL2135460","Vasopressin receptor agonist","Kidney function in hepatorenal syndrome","Hepatorenal syndrome","MONDO_0001382","Other","P, O",2022,"ENSG00000166148",2022,FALSE
"Mounjaro","Tirzepatide","Tirzepatide","Eli Lilly","CHEMBL4297839","GIP receptor and GLP1 receptor agonist","Type 2 diabetes","type 2 diabetes mellitus","MONDO_0005148","Autoimmune","S",2022,"ENSG00000112164; ENSG00000010310",2022,TRUE
"Imjudo","Tremelimumab","Tremelimumab","AstraZeneca","CHEMBL2108658","CTLA4-targeted mAb","Hepatocellular carcinoma","hepatocellular carcinoma","EFO_0000182","Oncology","S, O",2022,"ENSG00000163599",2022,TRUE
"Briumvi","Ublituximab","Ublituximab","TG Therapeutics","CHEMBL2108354","CD20-targeted mAb","Relapsing forms of multiple sclerosis","relapsing-remitting multiple sclerosis","EFO_0003929","Other","S",2022,"ENSG00000156738",2022,FALSE
"Voquezna Triple Pak","Vonoprazan; amoxicillin; clarithromycin","Vonoprazan","Phathom","CHEMBL2079130","Potassium-competitive acid blocker plus a penicillin class antibacterial plus a macrolide antimicrobial","Helicobacter pylori infection","Helicobacter pylori infectious disease","EFO_1000961","Infectious","P",2022,"ENSG00000186009; ENSG00000105675",2022,FALSE
"Voquezna Triple Pak","Vonoprazan; amoxicillin; clarithromycin","amoxicillin","Phathom","CHEMBL1082","Potassium-competitive acid blocker plus a penicillin class antibacterial plus a macrolide antimicrobial","Helicobacter pylori infection","Helicobacter pylori infectious disease","EFO_1000961","Infectious","P",2022,"",2022,FALSE
"Voquezna Triple Pak","Vonoprazan; amoxicillin; clarithromycin","clarithromycin","Phathom","CHEMBL1741","Potassium-competitive acid blocker plus a penicillin class antibacterial plus a macrolide antimicrobial","Helicobacter pylori infection","Helicobacter pylori infectious disease","EFO_1000961","Infectious","P",2022,"",2022,FALSE
"Amvuttra","Vutrisiran","Vutrisiran","Alnylam","CHEMBL4594511","TTR-targeted siRNA","Polyneuropathy of hereditary TTR-mediated amyloidosis","familial amyloid neuropathy","EFO_0004129","Other","S, O",2022,"ENSG00000118271",2022,TRUE
"Xenoview","Xenon Xe 129 hyperpolarized","Xenon Xe 129 hyperpolarized","Polarean","CHEMBL4594411","Hyperpolarized contrast agent","MRI-evaluation of lung ventilation",NA,NA,"Imaging","S",2022,"",NA,NA
